Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial

Divya Mohan, Holly R. Keir, Hollian Richardson, David Mayhew, Joseph Boyer, Marc P. van der Schee, Max D. Allsworth, Bruce E. Miller, Ruth Tal-Singer, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
29 Downloads (Pure)

Abstract

Background: Breath analysis is a burgeoning field, with interest in volatile organic compounds (VOCs) as a noninvasive diagnostic tool or an outcome measure, but no randomised controlled trials (RCTs) have yet evaluated this technology in a clinical trial longitudinally. In a pilot RCT, our exploratory objectives were feasibility of measuring VOCs via multiple techniques, assessing relationships between VOCs and Haemophilus colonisation and whether CXCR2 antagonism with danirixin altered lung microbiome composition in individuals with COPD.

Method: 43 participants had VOCs and sputum biomarkers evaluated. VOCs and induced sputum were collected after 6 h of fasting at screening and at days 1, 7 and 14. VOCs were analysed via gas chromatography mass spectrometry (GC-MS), field asymmetric ion mobility spectrometry (FAIMS) and eNose. The primary outcome for these analyses was the relationship between VOCs and Haemophilus abundance determined by 16S rRNA sequencing.

Results: A joint-effects model demonstrated a modest relationship between four exhaled VOCs and Haemophilus relative abundance (R2=0.55) measured only by GC-MS, but not as measured using gas chromtaography FAIMS or eNose. There was considerable variability in absolute quantities of individual VOCs longitudinally.

Conclusions: VOC measurement in clinical trials to identify subsets of COPD is feasible, but assessment of new VOC technologies must include concurrent GC-MS validation. Further work to standardise collection of VOCs and measuring a background or "housekeeper" VOC is required to understand and normalise individual VOC quantities.

Original languageEnglish
Article number00253-2021
Pages (from-to)1-9
Number of pages9
JournalERJ Open Research
Volume7
Issue number4
Early online date4 Oct 2021
DOIs
Publication statusPublished - Oct 2021

Fingerprint

Dive into the research topics of 'Exhaled volatile organic compounds and lung microbiome in COPD: a pilot randomised controlled trial'. Together they form a unique fingerprint.

Cite this